Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Cash & Equivalents: 2018-2021

Historic Cash & Equivalents for Black Diamond Therapeutics (BDTX) over the last 3 years, with Sep 2021 value amounting to $46.6 million.

  • Black Diamond Therapeutics' Cash & Equivalents fell 17.07% to $46.6 million in Q3 2021 from the same period last year, while for Sep 2021 it was $46.6 million, marking a year-over-year decrease of 17.07%. This contributed to the annual value of $34.6 million for FY2020, which is 77.63% down from last year.
  • According to the latest figures from Q3 2021, Black Diamond Therapeutics' Cash & Equivalents is $46.6 million, which was up 24.86% from $37.3 million recorded in Q2 2021.
  • In the past 5 years, Black Diamond Therapeutics' Cash & Equivalents ranged from a high of $357.2 million in Q1 2020 and a low of $14.1 million during Q1 2021.
  • Over the past 3 years, Black Diamond Therapeutics' median Cash & Equivalents value was $46.6 million (recorded in 2021), while the average stood at $84.3 million.
  • As far as peak fluctuations go, Black Diamond Therapeutics' Cash & Equivalents spiked by 698.78% in 2020, and later slumped by 96.05% in 2021.
  • Over the past 4 years, Black Diamond Therapeutics' Cash & Equivalents (Quarterly) stood at $51.7 million in 2018, then surged by 199.39% to $154.7 million in 2019, then plummeted by 77.63% to $34.6 million in 2020, then fell by 17.07% to $46.6 million in 2021.
  • Its last three reported values are $46.6 million in Q3 2021, $37.3 million for Q2 2021, and $14.1 million during Q1 2021.